NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
Clinical Trials
15 trialsNCT05588453 2026-01-12
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT00667953 2023-03-30
Study of Temzolomide and Gleevec in Advanced Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT00961844 2021-02-26
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Oslo University Hospital
Phase 1/2 Terminated
NCT01590082 2020-09-02
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01196416 2019-11-18
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00301067 2019-06-04
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
Northwestern University
Phase 1/2 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT00724841 2016-07-22
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT02065466 2016-04-21
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
Phase 1/2 Withdrawn
NCT01743157 2013-08-29
BBI
California Pacific Medical Center Research Institute
Phase 1/2 Completed
NCT00811759 2010-10-07
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00609011 2010-08-23
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
Myrexis Inc.
Phase 1/2 Completed
NCT00304200 2009-02-05
Temodar and Sutent as Therapy for Melanoma
Northern California Melanoma Center
Phase 1/2 Terminated